vestipitant Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Vestipitant (INN) is a drug developed by GlaxoSmithKline which acts as a selective antagonist for the NK1 receptor. It is under development as a potential antiemetic and anxiolytic drug, and as a treatment for tinnitus and insomnia.   Wikipedia

Chemistry

  • SMILES: C[C@@H](N(C)C(=O)N1CCNC[C@@H]1c2ccc(F)cc2C)c3cc(cc(c3)C(F)(F)F)C(F)(F)F
  • InChIKey: SBBYBXSFWOLDDG-JLTOFOAXSA-N
  • Mol. Mass: 491.45
  • ALogP: 5.93
  • ChEMBL Molecule:
    vestipitant  
More Chemistry

Pharmacology

Alternative names

1-piperazinecarboxamide, n-((1r)-1-(3,5-bis(trifluoromethyl)phenyl)ethyl)-2-(4-fluoro-2- methylphenyl)-n-methyl-, (2s)- | gw597599 | gw-597599 | gw597599b | vestipitant

Organizations (2)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Anxiety Disorders (Phase 2)

Depressive Disorder, Major (Phase 2)

Nausea (Phase 1)

Phobia, Social (Phase 2)

Postoperative Nausea and Vomiting (Phase 2)

Sleep Initiation and Maintenance Disorders (Phase 2)

Sleep Wake Disorders (Phase 2)

Tinnitus (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue